health Stories

Phase 3 trial confirms non-inferiority of hypofractionated locoregional radiotherapy versus standard radiotherapy for early breast cancer at 5 years.

FDA approval of a new dwarfism drug is a direct regulatory milestone with immediate clinical impact.

ARPA-H funding directed toward clinical trials for aging-related interventions signals significant institutional momentum in longevity medicine.

Review of CAR-T therapy applications in autoimmune rheumatic diseases highlights a significant emerging immunotherapy frontier.

Phase II trial of atezolizumab plus stereotactic radiation for triple-negative breast cancer brain metastasis provides important clinical immunotherapy data.

Review of investigational drugs in PTSD highlights a pipeline of emerging psychiatric treatments with significant unmet need.

FDA approval summary for pembrolizumab in HER2-positive gastric cancer is directly on-topic as a major immunotherapy regulatory milestone.

FDA approval summary for pembrolizumab in HER2-positive gastric cancer is directly on-topic as a major immunotherapy regulatory milestone.

Paltusotine is the first FDA-approved oral treatment for acromegaly, marking a significant therapeutic breakthrough for this rare endocrine disorder.

FDA approval of menopausal hormone therapy labeling changes is a significant regulatory update directly affecting women's health treatment.

Urolithin A mitophagy activation timing study shows prevention but not reversal of age-related cognitive impairment, a significant finding for longevity intervention strategy.

Microbiome depletion reversing brain aging features in aged mice is a significant finding for gut-brain aging axis and potential geroprotective interventions.

Comprehensive overview of FDA-approved drugs for ADHD treatment, directly relevant to drug approvals and clinical therapeutics.

ARPA-H funding clinical trials targeting aging signals growing institutional investment and translational momentum in longevity medicine.

U.S. withdrawal from WHO has significant implications for global pandemic preparedness and international disease surveillance cooperation.

Phase 2 randomized study shows vosoritide improves spine morphology in children with achondroplasia after one year, a significant clinical trial result for a rare disease therapy.

Randomized clinical trial (GUARDD-US) evaluating APOL1 genetic testing in hypertensive adults, with direct implications for precision medicine in kidney disease risk.

US withdrawal from WHO significantly impacts global pandemic preparedness and international disease surveillance cooperation.

Duplicate entry — Phase II nivolumab trial for unresectable cutaneous epithelial malignancies.

Duplicate entry — Phase II nivolumab trial for unresectable cutaneous epithelial malignancies.

Phase 3 randomized controlled trial evaluates once-weekly somapacitan growth hormone therapy in children with Noonan Syndrome.

Anti-CD7 fratricide-resistant CAR-T cell therapy shows potential for relapsed/refractory acute myeloid leukemia.

Comprehensive review of caloric restriction mechanisms in aging is a core longevity topic.

Analysis of polyploidy's role in cellular senescence is highly relevant to senescence research in aging biology.

Fight Aging analysis of clonal hematopoiesis and somatic mosaicism as drivers of degenerative aging is directly on-topic.

Research on gut microbiome changes driving age-related barrier dysfunction is directly relevant to aging biology mechanisms.

Fight Aging weekly newsletter aggregates longevity and aging research news directly relevant to the topic.

Epidemiological assessment of dietary choices on lifespan using UK Biobank data is directly relevant to longevity research.

Early clinical report of stem cell-derived islet transplantation restoring insulin independence in type 1 diabetes patients represents a potential breakthrough therapy.

Comprehensive review of all FDA-approved anticancer drugs from 2024 directly covers drug approvals and mechanisms across oncology indications.

Phase 3 trial results showing doravirine-islatravir non-inferiority to standard bictegravir regimen for initial HIV therapy represent a significant advance in antiretroviral options.

Reviews inflammaging mechanisms in aging liver disease and potential therapeutic interventions, directly relevant to aging biology.

Phase 3 trial of doravirine/islatravir versus bictegravir-based regimen for initial HIV-1 therapy provides key 48-week efficacy and safety data for a potential new first-line treatment.

Novel in utero CFTR modulator therapy for cystic fibrosis represents a significant potential treatment breakthrough for prenatal disease intervention.

Phase II-level study on liver transplantation after atezolizumab-bevacizumab downstaging of advanced hepatocellular carcinoma shows significant clinical benefit in a challenging cancer.

Comprehensive 2026 review of leukemia care and cure, covering current treatments and emerging therapeutic advances.

Phase 2 trial shows ipilimumab and nivolumab immunotherapy combined with chemoradiotherapy enables bladder-sparing treatment in muscle-invasive bladder cancer.

Phase 2b RCT of stem cell therapy (laromestrocel) for aging frailty is a significant clinical trial result in a novel therapeutic area.

Phase II multicenter RCT protocol for KCHO-1 herbal treatment in Alzheimer's disease represents a significant clinical trial development (duplicate entry).

Phase II multicenter RCT protocol for KCHO-1 herbal treatment in Alzheimer's disease represents a significant clinical trial development (duplicate entry).

Phase 2 RCT demonstrates efficacy and safety of mufemilast for Behçet's syndrome, a significant clinical trial result for a rare inflammatory disease.

Prospective clinical trial of neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer provides direct immunotherapy treatment evidence.

SHIELD trial evaluates fostemsavir safety and antiviral activity in pediatric HIV patients with multi-class antiretroviral resistance.

SHIELD trial evaluates fostemsavir safety and antiviral activity in pediatric HIV patients with multi-class antiretroviral resistance.

Comprehensive review of CRISPR-based gene therapy strategies for epidermolysis bullosa, directly relevant to novel gene therapy development.

Comprehensive review of CRISPR-based gene therapy strategies for epidermolysis bullosa, directly relevant to novel gene therapy development.

Multi-center clinical trial of allogeneic hematopoietic stem cell transplantation for transfusion-dependent thalassemia, directly relevant to treatment breakthroughs.

Phase 3 double-blind RCT (CIFFREO) reporting safety and efficacy of gene therapy fordadistrogene movaparvovec for Duchenne muscular dystrophy, a critical clinical trial result.

Phase 3 pragmatic RCT evaluating intensive task-specific training for recent spinal cord injury, providing significant rehabilitation trial evidence.

First-in-human phase 1/2a trial of T3011 oncolytic HSV expressing IL-12 and PD-1 antibody via intratumoral injection for advanced solid tumors including HNSCC, a novel immunotherapy approach.

Protocol for the HI-SIRI randomized controlled trial integrating infectious disease and substance use disorder treatment for severe injection-related infections, a significant public health intervention.

Phase 3 RCT of gene therapy fordadistrogene movaparvovec for Duchenne muscular dystrophy reports safety and efficacy results.

Review of neoadjuvant therapy advances for cisplatin-ineligible muscle-invasive bladder cancer including emerging agents TAR-200 and enfortumab vedotin plus pembrolizumab.

First-in-human phase 1/2a trial of oncolytic HSV T3011 expressing IL-12 and PD-1 antibody for advanced solid tumors including HNSCC.

RCT protocol for integrated infectious disease and substance use disorder treatment for severe injection-related infections.

Clinical validation of the first commercial immunoassay for plasma brain-derived tau, a significant diagnostic advance for neurological disease.